GSK (GSK) Stock Price, News & Analysis

Company Overview

GSK (GlaxoSmithKline plc) is a London-headquartered, multinational pharmaceutical and healthcare company formed through the 2000 merger of Glaxo Wellcome and SmithKline Beecham. The company is dual-listed and operates globally, developing, manufacturing and commercializing prescription medicines, vaccines and specialty treatments. Over its history GSK has evolved through portfolio reshaping and strategic transactions to focus on science-led pharmaceuticals and vaccines.

GSK’s core activities include research and development of therapies and vaccines across a range of therapeutic areas, commercial manufacturing, and global marketing. The company maintains an active R&D pipeline and engages in collaborations and partnerships with academic institutions and biopharmaceutical companies to advance new medicines. GSK is also a major shareholder in ViiV Healthcare, a specialist company focused on HIV treatment and prevention.

In recent years GSK completed a significant corporate reorganization, including the demerger of its consumer healthcare business into a separate company (Haleon) in 2022, allowing GSK to concentrate on pharmaceuticals and vaccines. The company sells products across North America, Europe, Asia-Pacific and emerging markets, operating manufacturing and R&D sites in multiple countries to support its global footprint.

GSK’s executive leadership is led by Chief Executive Officer Emma Walmsley, who has overseen the company’s strategic refocus toward innovation in medicines and vaccines. The firm emphasizes investment in R&D, strategic partnerships and pipeline development as central components of its long-term strategy in the global biopharmaceutical sector.

Key Stats

• Today's Range: $51.14 to $51.80
• 50-Day Range: $49.66 to $59.19
• 52-Week Range: $35.45 to $61.69
• Volume: 3.15 million shs
• Average Volume: 4.18 million shs
• Market Capitalization: $104.27 billion
• P/E Ratio: 13.35
• Dividend Yield: 3.52%
• Price Target: $53.00
• Consensus Rating: Reduce

GSK Stock Analysis - MarketRank™

GSK scored higher than 67% of companies evaluated by MarketBeat, and ranked 339th out of 866 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.4 / 5
• Analyst Rating: Reduce

Consensus Rating

GSK has received a consensus rating of Reduce. The company's average rating score is 1.90, and is based on no strong buy ratings, 2 buy ratings, 5 hold ratings, and 3 sell ratings.

Upside/Downside

The consensus price target for GSK is close to its current price, suggesting limited near-term upside or downside.

Amount of Analyst Coverage

GSK has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 5.34%

Earnings Growth

Earnings for GSK are expected to grow by 5.34% in the coming year, from $4.87 to $5.13 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of GSK is 13.35, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.00.

Price to Earnings Ratio vs. Sector

The P/E ratio of GSK is 13.35, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 21.04.

Price to Earnings Growth Ratio

GSK has a PEG Ratio of 2.63. PEG Ratios above 1 indicate that a company could be overvalued.

Price to Book Value per Share Ratio

GSK has a P/B Ratio of 4.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.72% of the float of GSK has been sold short.

Short Interest Ratio / Days to Cover

GSK has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GSK has recently decreased by 14.35%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 3.3 / 5
• Dividend Strength: Strong

Dividend Leadership

GSK is a leading dividend payer. It pays a dividend yield of 3.57%, putting its dividend yield in the top 25% of dividend-paying stocks.

Dividend Growth

GSK does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of GSK is 47.01%. This payout ratio is at a healthy, sustainable level, below 75%.

Dividend Sustainability

Based on earnings estimates, GSK will have a dividend payout ratio of 35.28% next year. This indicates that GSK will be able to sustain or increase its dividend.

News and Social Media

• Score: 3.5 / 5
• News Sentiment: 0.61

News Sentiment

GSK has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for GSK this week, compared to 8 articles on an average week.

Search Interest

23 people have searched for GSK on MarketBeat in the last 30 days. This is an increase of 15% compared to the previous 30 days.

MarketBeat Follows

14 people have added GSK to their MarketBeat watchlist in the last 30 days. This is an increase of 75% compared to the previous 30 days.

Company Ownership

• Score: 0.5 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GSK insiders have not sold or bought any company stock.

Percentage Held by Insiders

10.00% of the stock of GSK is held by insiders.

Percentage Held by Institutions

15.74% of the stock of GSK is held by institutions.

Company Calendar

• Last Earnings: 2/05/2026
• Record date for 4/9 Dividend: 2/20/2026
• Ex-Dividend for 4/9 Dividend: 2/20/2026
• Dividend Payable: 4/09/2026
• Record date for 7/9 Dividend: 5/15/2026
• Ex-Dividend for 7/9 Dividend: 5/15/2026
• Today: 5/23/2026
• Status update: 5/28/2026
• Jefferies Global Healthcare Conference 2026: 6/03/2026
• Dividend Payable: 7/09/2026
• Next Earnings (Estimated): 7/29/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NYSE
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NYSE:GSK
• CIK: 1131399
• Web: www.gsk.com
• Phone: 442080475000
• Fax: 44-20-8047-7807
• Employees: 66,841
• Year Founded: 2000

Price Target and Rating

• Average Price Target for GSK: $53.00
• High Price Target: $53.00
• Low Price Target: $53.00
• Potential Upside/Downside: +3.1%
• Consensus Rating: Reduce
• Rating Score (0-4): 1.90
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): $3.85
• Trailing P/E Ratio: 13.35
• Forward P/E Ratio: 10.55
• P/E Growth: 2.63
• Net Income: $7.54 billion
• Net Margins: 17.82%
• Pretax Margin: 22.75%
• Return on Equity: 44.28%
• Return on Assets: 11.49%

Debt

• Debt-to-Equity Ratio: 0.80
• Current Ratio: 0.79
• Quick Ratio: 0.52

Sales & Book Value

• Annual Sales: $43.07 billion
• Price / Sales: 2.42
• Cash Flow: $6.00 per share
• Price / Cash Flow: 8.56
• Book Value: $11.57 per share
• Price / Book: 4.44

Miscellaneous

• Outstanding Shares: 2,029,200,000
• Free Float: 1,826,278,000
• Market Cap: $104.27 billion
• Optionable: Optionable
• Beta: 0.38